Latest Aastrom Biosciences (ASTM) Headlines
Aastrom Biosciences to Host Fourth Quarter 2013 Investor Call on March 13, 2014
GlobeNewswire - Fri Mar 07, 2:59AM CST
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, announces the following webcast:
Aastrom Biosciences Enters Into $15 Million Equity Commitment With Lincoln Park Capital
GlobeNewswire - Mon Jan 27, 3:05PM CST
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announced today that it has entered into a stock purchase agreement with Lincoln Park Capital Fund, LLC ("Lincoln Park"), an institutional investor. Under the terms of the agreement, Aastrom has the right to sell up to $15 million in shares of common stock to Lincoln Park over a thirty-month period subject to certain limitations and conditions set forth in the purchase agreement.
Zacks #1 Rank Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 8:30AM CST
Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List for Monday
Incyte (INCY) Jumps: Stock Rises 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 7:57AM CST
Incyte Corp. (INCY) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
5 Stocks Under $10 Set to Soar
at The Street - Fri Jan 10, 6:00AM CST
These under-$10 stocks look ready to trade higher from current levels.
Peregrine Pharmaceuticals (PPHM) Soars: Stock Adds 14.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 07, 7:57AM CST
Peregrine Pharmaceuticals, Inc. (PPHM) was a big mover last session, as the company saw its shares rise over 14% on the day.
Synta Pharmaceuticals Corp. (SNTA) Catches Eye: Stock Surges 11.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 06, 7:44AM CST
Synta Pharmaceuticals Corp. was a big mover last session, as the company saw its shares rise nearly 12% on the day.
Biotech 2013 by the Numbers: A Blockbuster Year
at The Street - Wed Jan 01, 8:13AM CST
The biotech sector closed 2013 up 65%, greatly outperforming the broader markets.
Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia
GlobeNewswire - Thu Dec 19, 8:00AM CST
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that it has been granted a key composition-of-matter patent from the Australian Patent Office for ixmyelocel-T, Aastrom's cell therapy product candidate.
Aastrom Biosciences Regains Compliance With NASDAQ Equity Standard Listing Requirement
GlobeNewswire - Fri Nov 15, 8:00AM CST
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announced today that on November 14, 2013, the Company was notified that it has regained compliance with the NASDAQ Capital Market and its minimum market value of listed securities requirement. The Company regained compliance with NASDAQ Marketplace Rule 5550(b)(2) and was notified by NASDAQ that the delisting matter is now closed.
Aastrom Biosciences Reports Third-Quarter and Nine-Month 2013 Financial Results
GlobeNewswire - Tue Nov 12, 3:05PM CST
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today reported financial results for the quarter and nine months ended September 30, 2013.
Aastrom Biosciences to Present at the 2013 Therapeutic Area Partnerships Conference
GlobeNewswire - Tue Nov 12, 8:00AM CST
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that Nick Colangelo, President and CEO of Aastrom, will present at the 2013 Therapeutic Area Partnerships Conference on Tuesday, November 19 at 4:30 p.m. EST at the Hyatt Regency in Boston, MA. The conference organizers have selected ixmyelocel-T as a Top Project to Watch in advanced therapies.
Aastrom Biosciences to Host Third Quarter 2013 Investor Call on November 12, 2013
GlobeNewswire - Thu Nov 07, 3:05PM CST
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, announces the following webcast:
Aastrom Announces Results of Two Studies of Ixmyelocel-T Published in Stem Cell Research & Therapy
GlobeNewswire - Fri Nov 01, 11:10AM CDT
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that results from two separate research studies involving ixmyelocel-T, the company's lead product candidate, were published in the peer reviewed journal Stem Cell Research & Therapy.
Aastrom Biosciences Regains Compliance With NASDAQ Minimum Bid Requirement
GlobeNewswire - Thu Oct 31, 8:00AM CDT
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today reported that the company has regained compliance with the $1.00 minimum bid price requirement for continued listing under NASDAQ Listing Rule 5550(a)(2).
Downgrade Alert for Aastrom Biosciences (ASTM)
Comtex SmarTrend(R) - Tue Oct 29, 7:06AM CDT
Aastrom Biosciences (NASDAQ:ASTM) was downgraded from Buy to Hold at Maxim today. The stock closed yesterday at $4.06 on volume of 157,000 shares, below average daily volume of 1.6 million. In the past 52 weeks, shares of Aastrom Biosciences have traded between a low of $0.18 and a high of $6.25 and closed yesterday at $4.06, which is 2,156% above that low price. The 200-day and 50-day moving averages have moved 5.41% higher and 29.80% higher over the past week, respectively.
Aastrom Biosciences One-for-Twenty Reverse Stock Split Now Effective
GlobeNewswire - Wed Oct 16, 8:00AM CDT
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today reported that its previously announced one-for-twenty reverse stock split of the company's common stock is now effective. The reverse stock split is intended to increase the per share trading price of Aastrom's common stock to satisfy the $1.00 minimum bid price requirement for continued listing on NASDAQ and to attract greater institutional ownership of the company's shares. As a result of the reverse stock split, every twenty shares of the company's common stock that were issued and outstanding immediately prior to the opening of trading on October 16, 2013, will automatically be combined into one issued and outstanding share without any change in the par value of such shares. The number of authorized but unissued shares of the company's common stock will be proportionally reduced.
Aastrom Biosciences Announces One-for-Twenty Reverse Stock Split
GlobeNewswire - Thu Oct 10, 3:15PM CDT
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, announced today that its board of directors has approved a one-for-twenty reverse stock split of the company's common stock effective on October 16, 2013. The company has filed an amendment to its articles of incorporation to effect the reverse stock split, which was authorized by shareholders at Aastrom's special meeting on October 7, 2013. Following the reverse stock split, the company expects to have approximately 4.4 million shares of common stock outstanding.
Aastrom Biosciences to Present at the 2013 Stem Cell Meeting on the Mesa Conference
GlobeNewswire - Thu Oct 10, 8:00AM CDT
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that Nick Colangelo, President and CEO of Aastrom, will present at the 3rd Annual Regenerative Medicine Partnering Forum at the 2013 Stem Cell Meeting on the Mesa conference on Monday, October 14 at 10:30 a.m. PDT at the Estancia La Jolla Hotel in San Diego, CA.
Aastrom Biosciences to Host Fourth Quarter 2013 Investor Call on March 13, 2014
GlobeNewswire - Fri Mar 07, 2:59AM CST
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, announces the following webcast:
Aastrom Biosciences Enters Into $15 Million Equity Commitment With Lincoln Park Capital
GlobeNewswire - Mon Jan 27, 3:05PM CST
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announced today that it has entered into a stock purchase agreement with Lincoln Park Capital Fund, LLC ("Lincoln Park"), an institutional investor. Under the terms of the agreement, Aastrom has the right to sell up to $15 million in shares of common stock to Lincoln Park over a thirty-month period subject to certain limitations and conditions set forth in the purchase agreement.
Zacks #1 Rank Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 8:30AM CST
Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List for Monday
Incyte (INCY) Jumps: Stock Rises 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 7:57AM CST
Incyte Corp. (INCY) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
5 Stocks Under $10 Set to Soar
at The Street - Fri Jan 10, 6:00AM CST
These under-$10 stocks look ready to trade higher from current levels.
Peregrine Pharmaceuticals (PPHM) Soars: Stock Adds 14.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 07, 7:57AM CST
Peregrine Pharmaceuticals, Inc. (PPHM) was a big mover last session, as the company saw its shares rise over 14% on the day.
Synta Pharmaceuticals Corp. (SNTA) Catches Eye: Stock Surges 11.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 06, 7:44AM CST
Synta Pharmaceuticals Corp. was a big mover last session, as the company saw its shares rise nearly 12% on the day.
Biotech 2013 by the Numbers: A Blockbuster Year
at The Street - Wed Jan 01, 8:13AM CST
The biotech sector closed 2013 up 65%, greatly outperforming the broader markets.
Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia
GlobeNewswire - Thu Dec 19, 8:00AM CST
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that it has been granted a key composition-of-matter patent from the Australian Patent Office for ixmyelocel-T, Aastrom's cell therapy product candidate.
Aastrom Biosciences Regains Compliance With NASDAQ Equity Standard Listing Requirement
GlobeNewswire - Fri Nov 15, 8:00AM CST
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announced today that on November 14, 2013, the Company was notified that it has regained compliance with the NASDAQ Capital Market and its minimum market value of listed securities requirement. The Company regained compliance with NASDAQ Marketplace Rule 5550(b)(2) and was notified by NASDAQ that the delisting matter is now closed.
Aastrom Biosciences Reports Third-Quarter and Nine-Month 2013 Financial Results
GlobeNewswire - Tue Nov 12, 3:05PM CST
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today reported financial results for the quarter and nine months ended September 30, 2013.
Aastrom Biosciences to Present at the 2013 Therapeutic Area Partnerships Conference
GlobeNewswire - Tue Nov 12, 8:00AM CST
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that Nick Colangelo, President and CEO of Aastrom, will present at the 2013 Therapeutic Area Partnerships Conference on Tuesday, November 19 at 4:30 p.m. EST at the Hyatt Regency in Boston, MA. The conference organizers have selected ixmyelocel-T as a Top Project to Watch in advanced therapies.
Aastrom Biosciences to Host Third Quarter 2013 Investor Call on November 12, 2013
GlobeNewswire - Thu Nov 07, 3:05PM CST
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, announces the following webcast:
Aastrom Announces Results of Two Studies of Ixmyelocel-T Published in Stem Cell Research & Therapy
GlobeNewswire - Fri Nov 01, 11:10AM CDT
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that results from two separate research studies involving ixmyelocel-T, the company's lead product candidate, were published in the peer reviewed journal Stem Cell Research & Therapy.
Aastrom Biosciences Regains Compliance With NASDAQ Minimum Bid Requirement
GlobeNewswire - Thu Oct 31, 8:00AM CDT
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today reported that the company has regained compliance with the $1.00 minimum bid price requirement for continued listing under NASDAQ Listing Rule 5550(a)(2).
Downgrade Alert for Aastrom Biosciences (ASTM)
Comtex SmarTrend(R) - Tue Oct 29, 7:06AM CDT
Aastrom Biosciences (NASDAQ:ASTM) was downgraded from Buy to Hold at Maxim today. The stock closed yesterday at $4.06 on volume of 157,000 shares, below average daily volume of 1.6 million. In the past 52 weeks, shares of Aastrom Biosciences have traded between a low of $0.18 and a high of $6.25 and closed yesterday at $4.06, which is 2,156% above that low price. The 200-day and 50-day moving averages have moved 5.41% higher and 29.80% higher over the past week, respectively.
Aastrom Biosciences One-for-Twenty Reverse Stock Split Now Effective
GlobeNewswire - Wed Oct 16, 8:00AM CDT
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today reported that its previously announced one-for-twenty reverse stock split of the company's common stock is now effective. The reverse stock split is intended to increase the per share trading price of Aastrom's common stock to satisfy the $1.00 minimum bid price requirement for continued listing on NASDAQ and to attract greater institutional ownership of the company's shares. As a result of the reverse stock split, every twenty shares of the company's common stock that were issued and outstanding immediately prior to the opening of trading on October 16, 2013, will automatically be combined into one issued and outstanding share without any change in the par value of such shares. The number of authorized but unissued shares of the company's common stock will be proportionally reduced.
Aastrom Biosciences Announces One-for-Twenty Reverse Stock Split
GlobeNewswire - Thu Oct 10, 3:15PM CDT
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, announced today that its board of directors has approved a one-for-twenty reverse stock split of the company's common stock effective on October 16, 2013. The company has filed an amendment to its articles of incorporation to effect the reverse stock split, which was authorized by shareholders at Aastrom's special meeting on October 7, 2013. Following the reverse stock split, the company expects to have approximately 4.4 million shares of common stock outstanding.
Aastrom Biosciences to Present at the 2013 Stem Cell Meeting on the Mesa Conference
GlobeNewswire - Thu Oct 10, 8:00AM CDT
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that Nick Colangelo, President and CEO of Aastrom, will present at the 3rd Annual Regenerative Medicine Partnering Forum at the 2013 Stem Cell Meeting on the Mesa conference on Monday, October 14 at 10:30 a.m. PDT at the Estancia La Jolla Hotel in San Diego, CA.
